AUTHORS
Aikaterini Voulgaridou, MD, Athina Ntoumaziou, MD2, Yasmin Elgammal, MD3, John Leister, DO4, Zahra Hudda, MD5, Ammar Husami, MS6, Wenying Zhang, MD, PhD7, Theodosia M Kalfa Jr, MD, PhD8
AFFILIATIONS
1 Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
2 Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States
5 Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
6 Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
7 Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States, Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
8 Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
ABSTRACT
Diamond Blackfan anemia (DBA) is a rare inherited bone marrow failure (BMF) syndrome characterized by macrocytic anemia, reticulocytopenia, and selective bone marrow erythroid hypoplasia, typically presenting during infancy. In addition to hematologic manifestations, patients may exhibit congenital anomalies affecting the craniofacial, skeletal, cardiac, and renal systems. DBA is genetically heterogeneous, with 70%-80% of cases caused by heterozygous pathogenic variants in ribosomal protein (RP) genes. Despite widespread implementation of next-generation sequencing (NGS), disease-causing variants that reside outside coding and canonical splice-site regions remain challenging to identify, resulting in missed deep intronic mutations or leaving variants of uncertain significance (VUS) unresolved.
To address this limitation, we implemented an integrated genomic-transcriptomic approach combining whole-genome sequencing (WGS) with RNA sequencing (RNA-seq) of patient-derived EBV-immortalized lymphocytes. This strategy enabled the identification and functional characterization of deep intronic RP gene variants that alter splicing through activation of cryptic splice sites and pseudoexon (PE) inclusion, resulting in premature termination (PT) and reduced functional protein expression.
In the first family, a 5-year-old girl presented at 12 months of age with severe macrocytic anemia (hemoglobin 6.5 g/dL, MCV 102 fL), thrombocytosis, and bone marrow findings consistent with erythroid hypoplasia without overt dysplasia or increased blasts. Chromosome analysis, Fanconi anemia testing, and erythrocyte ADA levels were unremarkable. Family history was notable for unexplained anemia in her father, who required transfusions in early adulthood; his anemia resolved but he continued to have macrocytosis and thrombocytosis. WGS identified a novel paternally inherited deep intronic RPS26 variant, NM_001029.5:c.182-364A>G. In silico analysis predicted aberrant splicing through the gain of a novel acceptor splice site located 74 bp upstream of the variant and a novel donor splice site located 1 bp upstream of the variant. The predicted consequence was inclusion of a 74-bp PE between exons 2 and 3, resulting in a PT, p.(Ala61Glyfs*34). RNA-seq analysis confirmed aberrant splicing, with Sashimi plots demonstrating the mutant transcript in both the proband and her affected father. These findings strongly support the pathogenicity of the variant and provide molecular confirmation of DBA.
The second case is a 7-year-old girl, born small for gestational age, with multiple congenital anomalies including cleft lip/palate, craniofacial dysmorphism, bilateral sandal-gap deformities, and congenital heart disease. At birth, she was noted to have severe macrocytic anemia (hemoglobin 7.2 g/dL, MCV 107.5 fL), reticulocytopenia, elevated erythrocyte ADA, and bone marrow findings consistent with DBA. Trio whole-exome sequencing, BMF panel testing, and DEB studies were unrevealing. She required chronic transfusion support during infancy, achieved partial response to corticosteroids, but later developed recurrent transfusion dependence and ultimately underwent matched unrelated donor hematopoietic stem cell transplantation at 7 years of age. WGS identified a deep intronic RPL5 variant, NM_000969.5:c.325-380A>G, which was recently reported in a patient with a phenotype consistent with DBA6. In silico analysis predicted activation of cryptic acceptor and donor splice sites, resulting in inclusion of a 79-bp PE between exons 4 and 5. This aberrant splicing event is predicted to cause a frameshift and PT, p.(Leu109Trpfs*4), which was confirmed by RNA sequencing. These findings provide functional evidence that links the RPL5 variant to the patient's DBA phenotype.
These cases highlight important diagnostic blind spots of exon-centric sequencing approaches and demonstrate the value of transcriptomic analysis for resolving noncoding variants in DBA. Functional RNA-seq studies enable direct visualization of aberrant splicing events, facilitate reclassification of deep intronic VUS as pathogenic, and provide definitive molecular diagnoses where standard testing has been inconclusive. These findings inform genetic counseling, treatment decisions, and surveillance for DBA-associated complications. Our results establish transcriptome-based diagnostics as a powerful complement to WGS and an essential tool in the precision evaluation of inherited BMF syndromes and rare anemias.
DISCLOSURES
Aikaterini Voulgaridou, MD: No relevant conflicts of interest to declare.